Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy
暂无分享,去创建一个
Y. Nakanuma | H. Bukawa | T. Yanagawa | E. Warabi | T. Horibe | K. Kawakami | J. Shoda | M. Kohno | K. Seto | Kahori Seto
[1] H. Bukawa,et al. Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma. , 2013, Oncology reports.
[2] R. Puri,et al. Targeting Interleukin-4 Receptor α with Hybrid Peptide for Effective Cancer Therapy , 2011, Molecular Cancer Therapeutics.
[3] T. Horibe,et al. Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer. , 2011, Biochemical and biophysical research communications.
[4] T. Horibe,et al. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells , 2011, BMC Cancer.
[5] R. Verma,et al. Therapeutic potential of anticancer immunotoxins. , 2011, Drug discovery today.
[6] T. Horibe,et al. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity. , 2011, Biochemical and biophysical research communications.
[7] T. Horibe,et al. A novel hybrid peptide targeting EGFR-expressing cancers. , 2011, European journal of cancer.
[8] R. Puri,et al. Targeting IL‐13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL‐13‐PE and gemcitabine , 2011, International journal of cancer.
[9] T. Horibe,et al. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent , 2011, Journal of Translational Medicine.
[10] T. Gruenberger,et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. , 2010, The Lancet. Oncology.
[11] D. Cunningham,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.
[12] R. Puri,et al. Potent in vitro and in vivo antitumor activity of interleukin‐4‐conjugated Pseudomonas exotoxin against human biliary tract carcinoma , 2008, International journal of cancer.
[13] H. Safran,et al. Lapatinib/Gemcitabine and Lapatinib/Gemcitabine/Oxaliplatin: A Phase I Study for Advanced Pancreaticobiliary Cancer , 2008, American journal of clinical oncology.
[14] R. Puri,et al. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. , 2007, Cancer Research.
[15] T. Okusaka,et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer , 2006, Cancer Chemotherapy and Pharmacology.
[16] I. Pastan,et al. Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2 , 2006, Journal of immunotherapy.
[17] M. Miwa,et al. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). , 2005, World journal of gastroenterology.
[18] N. Tepsiri,et al. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. , 2005, World journal of gastroenterology.
[19] Anthony Asher,et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma , 2003, Journal of Neuro-Oncology.
[20] H. Thomas,et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998 , 2001, Gut.
[21] T. Patel. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.
[22] Ira Pastan,et al. Immunotoxins in cancer therapy. , 1999, Current opinion in investigational drugs.
[23] T. Ohno,et al. The invasion potentials of human biliary tract carcinoma cell lines: correlation between invasiveness and morphologic characteristics. , 1998, International journal of oncology.
[24] 勝彦 齋藤,et al. ヒト肝内胆管癌の株化(CCKS1)樹立 , 1993 .
[25] M. Kojiro,et al. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (KMBC) , 1992, Cancer.
[26] W. Dippold,et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. , 1985, Journal of hepatology.